Desktop Broker TV

In this episode of From the Helm, Grady Wulff sits down with Cynata Therapeutics (ASX:CYP) CEO, Kilian Kelly, to discuss the company’s pioneering work in stem cell and regenerative medicine. Kilian shares insights on Cynata’s mesenchymal stromal cell (MSC) platform, its unique “one donor, one time” approach, the path to commercialisation, and what investors can expect in the coming year.

In this interview, Grady covers:

• (0:29) an introduction to Cynata and its core technology
• (1:05) the role and importance of mesenchymal stromal cells (MSCs)
• (2:06) how Cynata addresses the challenges facing MSC therapies
• (3:24) the game-changing “one donor, one time” model
• (8:09) Cynata’s pipeline of assets in development
• (9:10) balance sheet strength and funding position
• (9:56) how Cynata compares with ASX peers
• (10:52) expected news flow over the next 12 months.

This interview was recorded on Thursday, 11 September 2025.